Dendreon to expand DTC in effort to spur demand

Share this article:
Dendreon calls in air reinforcements for Provenge
Dendreon calls in air reinforcements for Provenge

Dendreon is expanding its DTC campaign, an analyst says, as the firm sees slack demand for its Provenge prostate cancer vaccine and a nascent threat from Johnson & Johnson's Zytiga.

The company plans to extend consumer marketing into new regions as additional centers come on board to administer the vaccine, noted Collins Stewart analyst Salveen Richter in an investor note after meeting with management last week.

Dendreon has not disclosed the specific regions, Richter told MM&M, and Dendreon did not respond to reporter e-mails.

The expansion comes on the heels of a revised marketing strategy the firm undertook in July that also included adding sales reps with urology experience to ensure urologists understand the vaccine's four-month survival benefit and are educated on reimbursement/infusions, among other suggested changes to their treatment paradigm. Most of Dendreon's reps now have oncology experience.

“Current Provenge sales come largely from oncologists, however, most recently-enrolled centers are urology practices,” wrote Richter.

Sales have been disappointing so far. The drug was approved early last year, and in August Dendreon withdrew its Provenge sales forecast because it was taking longer than expected for doctors to become comfortable with the buy-and-bill scheme for the product, which costs $93,000 per treatment. Doctors must front the cost while waiting for reimbursement.

J&J's Zytiga, a pill approved in August for advanced prostate cancer patients that have failed to benefit from chemotherapy, is providing "limited competition" to Provenge, Richter noted. Zytiga also prolonged life by about four months in clinical trials.

Given Provenge's lackluster sales, combined with clinician unease regarding the high up-front cost, Richter forecasts the company's marketing efforts could help it reach annual sales of just $500 million. That's a far cry from the blockbuster expectations analysts once had for the treatment.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...